【レポートの概要（一部）】
1. Report Overview
1.1 Global RNAi Therapies Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to RNAi Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of RNA: From DNA to Proteins, and Beyond
2.2.1 The Functions of RNA
2.2.2 The Discovery of RNA Interference
2.3 RNAi Timeline: From Discovery to Human Trials
2.4 RNAi: Repurposing a Natural Cellular Gene-Silencing Process
2.4.1 siRNA: Application in Genetic Diseases
2.4.2 miRNA: Natural Gene Expression Regulators
2.5 Development of RNAi Therapies
2.5.1 The Delivery Approach: Exogenous Introduction of siRNA
2.5.2 ddRNAi: Stable Expression of RNAi Inducers
2.5.2.1 shRNA: Employing Viral Vectors
2.6 Ribopharma AG: The First Company to Specialise in RNAi Therapeutics
2.7 Phases of Clinical Trials
2.8 Scope of This Report
2.8.1 Products Excluded from This Report
2.9 Currency Exchange Rates in This Report
3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Areas Driving the RNAi Therapeutics Market to 2025
3.2 Infectious Diseases and Cancer Account for Most Pipeline Therapies in 2015
3.3 Infectious Diseases – Protecting and Saving Lives through Medical Progress
3.3.1 Viral Hepatitis
3.3.1.1 Hepatitis B and C
3.3.1.2 Prospects for RNAi in Hepatitis B and C
3.3.2 Prospects for RNAi in HIV Infection
3.4 Cancer: Great Scope for New Therapies
3.5 Ophthalmic Diseases – Limited Opportunity for Developers?
3.5.1 RNAi for AMD: No Clinical Candidates in 2015
3.5.2 RNAi for Glaucoma: Limited Role in Treatment?
3.6 Lung Diseases and Respiratory Disorders – Life-Improving Treatments
3.6.1 Respiratory Syncytial Virus Infection
3.7 Kidney Disease – Investigations to Treat the Urinary System
3.7.1 Delayed Graft Function (DGF)
4. RNAi Therapies: World Market 2015-2025
4.1 The World RNAi Therapies Market in 2014
4.2 RNAi Therapies Market Segmentation, 2014
4.3 World RNAi Therapies Market: Sales Forecast 2015-2025
4.4 World RNAi Therapies Market: Drivers and Restraints 2015-2025
5. Leading Regional Markets 2015-2025
5.1 Scope and Limitations
5.2 World RNAi Therapies Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change to 2025?
5.4 US RNAi Therapies Market 2015-2025
5.4.1 FDA Approval of Kynamro Improves RNAi Prospects
5.5 EU5 RNAi Therapies Market 2015-2025
5.5.1 RNAi Prospects in Leading EU Markets
5.6 Asia-Pacific RNAi Therapies Market 2015-2025
5.6.1 Prospects for RNAi Therapies in Japan
5.6.2 China Steps Up Efforts in RNAi Drug Development
5.6.3 India: Company Collaborations to Stimulate Interest in RNAi
5.7 Latin American RNAi Therapies Market 2015-2025
5.8 The RNAi Therapies Market in the Rest of the World 2015-2025
6. RNAi Therapies: Leading Companies 2015-2025
6.1 Alnylam Pharmaceuticals
6.1.1 RNAi Therapeutic Pipeline: Strong Portfolio
6.1.1.1 Genetic Medicine STAr
6.1.1.2 Cardio-metabolic Disease STAr
6.1.1.3 Hepatic Infectious Disease STAr
6.1.1.4 Other Pipeline Products: Development on Hold
6.1.1.5 Other Pipeline Products: ALN-RSV01 for RSV Infection
6.1.1.6 Other Pipeline Products: ALN-VSP02 for Liver Cancers
6.1.2 Sales and Recent Performance
6.1.3 Recent Developments
6.1.3.1 Alnylam Files Trade Secret Misappropriation Suit Against Dicerna
6.1.3.2 Alnylam Enters Strategic Alliance with Genzyme (Sanofi)
6.1.3.3 Other Alliances with Leading Companies
6.1.3.4 Acquisition of Sirna Therapeutics
6.1.3.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.2 Arrowhead Research
6.2.1 RNAi Therapeutic Pipeline: Targeting Hepatitis B and Alpha-1 Antitrypsin Deficiency
6.2.2 Sales and Recent Performance
6.2.3 Recent Developments
6.2.3.1 Roche Acquisition Strengthens Company’s Market Position
6.2.3.2 Arrowhead Acquires Novartis’ RNAi Assets
6.3 Benitec Biopharma
6.3.1 RNAi Therapeutic Pipeline
6.3.2 Sales and Recent Performance
6.3.3 Recent Developments
6.3.3.1 ddRNAi Patent Maintained by Australia’s CSIRO
6.3.3.2 Agreement with Omnia Biologics
6.4 Gradalis Incorporated
6.4.1 RNAi Therapeutic Pipeline: Advancing Gradalis for Cancer
6.5 Quark Pharmaceuticals
6.5.1 RNAi Therapeutic Pipeline: A Broad siRNA Portfolio in Clinical Development
6.5.1.1 Preclinical Pipeline: Collaboration with Nitto Denko
6.5.2 Recent Developments
6.5.2.1 Quark Partners with Big Pharma to Develop RNAi Therapies
6.5.2.2 RiboQuark: Joint Venture with Suzhou Ribo Life Science
6.6 Roche Innovation Center Copenhagen
6.6.1 RNAi Therapeutic Pipeline: Potential in Locked Nucleic Acid Platform?
6.6.1.1 Former Santaris Pipeline Candidates
6.6.2 Recent Developments
6.6.2.1 Targeting Rare Genetic Diseases through Alliance with Shire
6.6.2.2 Roche and Isis Pharmaceuticals to Settle Patent Lawsuit?
6.7 RXi Pharmaceuticals
6.7.1 RNAi Therapeutic Pipeline: Lead Candidate RXI-109 Prevents Scar Formation
6.7.2 Sales and Recent Performance
6.7.3 Recent Developments
6.7.3.1 Early Distribution Agreement with Ethicor
6.7.3.2 Acquisition of RNAi Assets from OPKO Health
6.8 Silence Therapeutics
6.8.1 RNAi Therapeutic Pipeline: Lead Candidate Atu027 Completed Phase 2
6.8.1.1 Multiple Delivery Technologies Offers Promise
6.8.2 Sales and Recent Performance
6.8.3 Recent Developments
6.8.3.1 Partnerships for Silence Therapeutics’ RNAi Platform
6.8.3.2 Silence Therapeutics Wins European Patent Office Appeal Covering RNAi Trigger Modification
6.9 Silenseed
6.9.1 RNAi Therapeutic Pipeline
6.9.2 Recent Developments
6.9.2.1 Silenseed IPO Filed in 2014
6.10 Sylentis
6.10.1 RNAi Therapeutic Pipeline: First Spanish Company to Conduct Clinical Trials of an RNAi Drug
6.10.2 Recent Developments
6.10.2.1 Zeltia Subsidiary PharmaMar May Merge with Its Parent Company
6.11 Tekmira Pharmaceuticals
6.11.1 RNAi Therapeutic Pipeline: Focusing on Cancer and Ebola
6.11.2 Sales and Recent Performance
6.11.3 Recent Developments
6.11.3.1 Out-Licensing of LNP Technology Adding Extra Revenue
6.11.3.2 Tekmira Merges with OnCore
6.12 Other Companies of Interest
7. RNAi Therapies: Development Pipeline 2015-2025
7.1 The RNAi Therapies Pipeline
7.2 RNAi Therapies: Phase 3 Pipeline
7.2.1 ALN-TTR02 (patisiran, Alnylam)
7.2.1.1 ALN-TTR02: Sales Forecast 2015-2025
7.2.2 ALN-TTRsc (revusiran, Alnylam)
7.2.2.1 ALN-TTRsc: Sales Forecast 2015-2025
7.2.3 Vigil (Cancer Immunotherapy, Gradalis Incorporated)
7.2.3.1 Vigil: Sales Forecast 2015-2025
7.3 RNAi Therapies: Phase 2 Pipeline
7.3.1 ALN-RSV01 (targeting RSV nucleocapsid, Alnylam)
7.3.2 ARC-520 (targeting conserved regions of HBV, Arrowhead)
7.3.2.1 ARC-520 Clinical Trial Results and Analysis
7.3.2.2 ARC-520: Sales Forecast 2015-2025
7.3.3 Atu027 (targeting PKN3, Silence Therapeutics)
7.3.3.1 Atu027: Sales Forecast 2015-2025
7.3.4 PF-655 (RTP801I-14) (targeting RTP801, Quark)
7.3.4.1 PF-655: Sales Forecast 2015-2025
7.3.5 QPI-1002 (I5NP) (targeting p53, Quark)
7.3.5.1 QPI-1002: Sales Forecast 2015-2025
7.3.6 RXI-109 (targeting CTGF, RXi Pharmaceuticals)
7.3.6.1 RXI-109: Sales Forecast 2015-2025
7.3.7 siG12D-LODER (targeting KRAS, Silenseed)
7.3.7.1 siG12D-LODER: Sales Forecast 2015-2025
7.3.8 SPC3649 (miravirsen) (targeting miR-122, Roche)
7.3.8.1 SPC3649: Sales Forecast 2015-2025
7.3.9 SYL040012 (targeting ADRB2, Sylentis Pharmaceuticals)
7.3.9.1 SYL040012: Sales Forecast 2015-2025
7.3.10 SYL1001 (targeting TRPV1, Sylentis Pharmaceuticals)
7.3.11 TKM-PLK1 Products (targeting PLK1, Tekmira)
7.3.12 TT-034 (targeting Hepatitis C Virus, Benitec Biopharma)
7.4 RNAi Therapies: Phase 1 Pipeline
7.5 RNAi Therapies: Preclinical Pipeline
8. Qualitative Analysis of the RNAi Therapies Market 2015-2025
8.1 SWOT Analysis of the RNAi Therapies Market
8.2 Strengths
8.2.1 A Highly Specific and Selective Therapy
8.2.2 Lower Therapeutic Dosages
8.2.3 Shorter Lead Identification Times
8.2.4 Manufacturing Synthetic RNAs: Cost-Effective and Easier Than for Other Biologics
8.3 Weaknesses
8.3.1 Challenges of Systemic Delivery of RNAi
8.3.1.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
8.3.1.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
8.3.1.3 Industry’s Approach to Overcome the Introduction Challenges
8.3.2 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
8.4 Opportunities
8.4.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
8.4.2 Combination Therapy with Antisense Technology or Aptamers?
8.4.2.1 Antisense Technology: First-to-Market Advantage
8.4.2.2 Aptamers: Offering Advantages over Antibodies
8.4.3 The Untapped Potential of mRNA
8.5 Threats
8.5.1 Novel Class of Treatment May Have Prolonged Approval Process
8.5.2 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
8.5.3 Advances in Alternative Gene-Silencing Approaches Such As CRISPRs
8.6 STEP Analysis of the RNAi Therapies Market
8.6.1 Social Factors
8.6.2 Technological Factors
8.6.3 Economic Factors
8.6.4 Political Factors
9. Research Interviews
9.1 Interview with Mr Joseph Payne, CEO of Arcturus Therapeutics, San Diego, California
9.1.1 Arcturus Therapeutics’ RNAi Therapies Pipeline
9.1.2The Outlook for TTR-Mediated Disease RNAi Therapies?
9.1.3 Barriers to Market Entry
9.1.4 Opportunities for RNAi Developers
9.1.5 Interest from Big Pharma and Investors
9.1.6 Therapeutic Areas and Targets for RNAi Developers
9.1.7 Other Trends and Developments in RNAi Therapeutics
9.2 Interview with Mr J. Michael French, President and CEO of Marina Biotech, Bothell, Washington
9.2.1 Marina Biotech’s RNAi Pipeline and Platform
9.2.2 Barriers to Market Entry
9.2.3 Opportunities for RNAi Developers
9.2.4 Interest from Big Pharma and Investors
9.2.5 Therapeutic Areas and Targets for RNAi Developers
9.2.6 Other Trends and Developments in RNAi Therapeutics
10. Conclusions
10.1 Market Entry of RNAi Therapies Expected in 2015-2025
10.2 The World RNAi Therapies Market in 2014
10.3 Leading RNAi Therapies Companies
10.4 Leading Regional Markets
10.5 World RNAi Therapies Market Forecast 2015-2025
10.6 RNAi Therapies Late-Stage Pipeline
10.7 The Future of the RNAi Therapies Market: Time for a RNAissance?
11. Glossary
【レポート販売概要】
■ タイトル：RNA干渉（RNAi）治療の世界市場：siRNA、shRNA、ddRNAiアプローチの展望■ 英文：RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches
■ 発行日：2015年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN50611
■ 調査対象地域：グローバル
- ポリアリールスルホン（PAS）の世界市場：製品別（ポリフェニルスルホン（PPSU）、ポリエーテルイミド（PEU）、ポリエーテルスルホン（PESU）、地域別、セグメント予測The global polyarylsulfone market is expected to reach USD 2.9 billion by 2025, according to a new report by Grand View Research, Inc. Growing application in medical device & technology applications such as blood filtration membranes, dental instruments, surgical devices, and medium-sized containers emerged as a significant demand driver for the PAS market. Polyarylsulfone (PAS) share numerous app …
- 高リン血症治療薬の世界市場2015-2019About hyperphosphatemia Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulti …
- 世界のWi-Fi対応端末市場予測Driven by the flourishing demand for smartphones and IoT (Internet of Things), global shipment volume of Wi-Fi (Wireless-Fidelity) connected devices reached around 2.27 billion units in 2014, up 18% year-on-year. In anticipation of continued strong demand in the future for PCs, smart handheld devices and broadband CPE (Customer Premise Equipment), a wide range of ICT brands and new internet servic …
- ACドライブの世界市場予測（～2021年）：低電圧ACドライブ、中電圧ACドライブThe global AC drives market is projected to grow at a CAGR of 7.0% from 2016 to 2021, to reach a market size of USD 22.07 Billion by 2021. This growth is attributed to the increasing urbanization & industrialization, rising need for energy efficiency, and regulations on energy efficiency. The report segments the AC drives market based on end-user industries into oil & gas, water & wastewater, powe …
- 加入者データ管理市場（The Subscriber Data Management (SDM) Market: 2012 – 2016）Subscriber data is a principal asset held by network carriers. Subscriber Data Management (SDM) allows carriers to consolidate and manage their cross domain subscriber data encompassing access preferences, authentication, services, identities, location, and presence into unified data repositories. Besides enabling considerable OPEX reductions and allowing carriers to deliver more personalised serv …
- 飼料用特殊添加物の世界市場：腸健康/消化機能、カビ毒管理、旨さ、保存/機能性成分The specialty feed additives market is gaining momentum over the last few years and this trend is projected to continue. The specialty feed additives market is projected to reach $11.9 billion by 2020, at a CAGR of 4.5% from 2015 to 2020. The market is driven by factors such as swelling demand for protein rich meat products worldwide, industrialization in meat production, and rising awareness towa …
- セラミックコーティングの世界市場2016-2020：酸化物系セラミックコーティング、炭化ケイ素系セラミックコーティング、窒化系セラミックコーティングAbout Ceramic Coatings Ceramic coatings resist wear, tear, erosion, and high temperature on a wide range of application areas, such as automotive, aerospace and defense, energy, and healthcare. The automotive industry is the major end-user segment for ceramic coatings. Automobile headers, exhaust pipes, and turbocharger parts are usually ceramic coated to protect them from chemicals, heat, and exh …
- 自動パーキングシステムの世界市場予測（～2027年）“Increasing number of vehicles and scarcity of land coupled with the need for low emission sustainable parking solution to boost the automated parking system market”The automated parking system market is estimated to be USD 1.3 billion in 2019 and is projected to grow at a CAGR of 13.1% during the forecast period (2019–2027) to reach a market size of USD 3.6 billion by 2027. The key advantage of a …
- 軍用航空機向け情報・監視・偵察（ISR）技術の世界市場2016-2026This brand new report from business intelligence provider visiongain offers thorough analysis of the global military airborne ISR market and future prospects. Visiongain assesses that the airborne ISR market will generate revenues of $26,672m in 2016. Now: “Finmeccanica to Supply Angola with Maritime Surveillance Equipment, Craft”. This is one example of the business relevant headline that you nee …
- 転売チケットの世界市場：コンサートチケット、映画チケット、スポーツチケットThe global market for secondary tickets is expected to exhibit significant growth during the forecast period and is positively affected by the recent increase in the number of sporting and live events. This recent rise in the number of sporting and live events is envisaged to result in this market’s remarkable CAGR of more than 19% by 2020. Technavio market research analysts estimate eminent facto …
- 事業提携・ライセンシング・投資・M&A動向：December 2012（製薬業界）Partnerships, Licensing, Investments and M&A Deals and Trends For December 2012 In Pharmaceuticals Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends For December 2012 In Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report pro …
- 世界のリップケア用品市場動向（2012-2016）TechNavio's analysts forecast the Global Lip Care Products market to grow at a CAGR of 4.58 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand for natural and organic lip care products. The Global Lip Care Products market has also been witnessing an increased use of lip care products by men. However, the threat of counterfeit products …
- Gantenerumab (Alzheimer’s Disease)：市場予測と分析（～2022）Gantenerumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gantenerumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic ther …
- E911 and NG 911: Expanding Intellectual Property Beyond EmergenciesEnhanced 911 services is a tight ecosystem. There are a few leaders in control of all key customers. Each lead provider controls a niche that overlaps with other providers. Whilst revenue for most of the leads is secure due to lengthy government contracts, the stock gains are negligible. There are options in portfolio restructuring for the leaders ? acquire or develop new technologies and sales ch …
- 世界の軍用固定翼航空機の市場動向2013-2023：地域別分析"The Global Military Fixed-Wing Aircraft Market 2013-2023 - Country Analysis: Market Profile" provides details of the key markets in each region, offering an analysis of the top segments of Military Fixed-Wing Aircraft, expected to be in demand. It also investigates the top three expected Military Fixed-Wing Aircraft programs, in terms of demand in the key markets in each region.
